Loading...
Docoh
Log in Free sign up

Vaxart (VXRT)

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart has believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include tablet vaccines designed to protect against coronavirus, Norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immuno-oncology indication. Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Company profile

Ticker
VXRT
Exchange
NASDAQ
Website
vaxart.com
CEO
Andrei Floroiu
Employees
Incorporated
Delaware
Location
California
Fiscal year end
Dec 31
Sector
Manufacturing > Biological Product (except Diagnostic) Manufacturing
Industry (SIC)
Biological Products, (No Diagnostic Substances)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne ...
Former names
Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI /DE/, NABI BIOPHARMACEUTICALS, NORTH AMERICAN BIOLOGICALS INC
SEC CIK
0000072444
Corporate docs
Subsidiaries
Vaxart Biosciences, Inc. • Biota Holdings • Biota Scientific Management Pty, Ltd. ...
IRS number
591212264

VXRT stock data

News

From Benzinga Pro
Vaxart Q2 EPS $(0.23) Misses $(0.21) Estimate
8 Aug 22
Vaxart (NASDAQ:VXRT) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 76.92 percent decrease over losses of $(0.13) per share from the same
Vaxart Initiates Work on Vaccine Candidates That Directly Target New Omicron Variants of Concern
8 Aug 22
In its business update today for the second quarter of 2022, Vaxart, Inc.
Earnings Scheduled For August 8, 2022
8 Aug 22
Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter.
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
20 Jul 22
Vaxart Publishes Clinical Data Suggesting Its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses That Are Highly Cross-Reactive
20 Jul 22

Press releases

From Benzinga Pro
Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results
8 Aug 22
Top-line data from COVID-19 Phase II study expected in the third quarter of 2022 Vaxart initiates work on vaccine candidates that directly target new omicron variants of concern Positive data from norovirus trial in
Vaxart Stockholders Approve Proxy Proposals 2, 3 and 4
5 Aug 22
All six proposals approved in the 2022 Proxy Statement Vote strengthens the Company as it progresses its oral vaccine programs SOUTH SAN FRANCISCO, Calif., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT)
Vaxart to Host Second Quarter 2022 Business Update and Financial Results Conference Call on August 8
28 Jul 22
SOUTH SAN FRANCISCO, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2022 after
Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022
14 Jul 22
Thinking about trading options or stock in DoorDash, Merck, General Mills, Apple, or Vaxart?
6 Jul 22

Analyst ratings and price targets

Last 3 months
B. Riley Securities
Maintains
Neutral
$6.00
19 May 22

Calendar

8 Aug 22
16 Aug 22
31 Dec 22

Financial summary

Financial statements Chart VXRT financial data
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 91.47M 91.47M 91.47M 91.47M 91.47M 91.47M
Cash burn (monthly) 10.65M 6.15M 9.81M 8.02M 8.63M 6.76M
Cash used (since last report) 16.73M 9.66M 15.41M 12.61M 13.57M 10.62M
Cash remaining 74.74M 81.8M 76.06M 78.86M 77.9M 80.85M
Runway (months of cash) 7.0 13.3 7.8 9.8 9.0 12.0

Beta Read what these cash burn values mean

Financial data from Vaxart earnings reports.

Recent insider trades

VXRT insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
4 Aug 22 Julie M Cherrington Common Stock Grant Acquire A No No 0 6,217 0 6,217
4 Aug 22 Julie M Cherrington Stock Option Common Stock Grant Acquire A No No 3.91 37,280 145.76K 37,280
4 Aug 22 Davis Todd C Common Stock Grant Acquire A No No 0 7,375 0 125,905
4 Aug 22 Davis Todd C Stock Option Common Stock Grant Acquire A No No 3.91 44,224 172.92K 44,224
4 Aug 22 Finney Michael J. Common Stock Grant Acquire A No No 0 7,375 0 663,465
4 Aug 22 Finney Michael J. Stock Option Common Stock Grant Acquire A No No 3.91 44,224 172.92K 44,224
4 Aug 22 Wheadon David E. Common Stock Grant Acquire A No No 0 7,375 0 7,375
4 Aug 22 Wheadon David E. Stock Option Common Stock Grant Acquire A No No 3.91 44,224 172.92K 44,224
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

VXRT institutional ownership history Ownership history
35.5% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 144 147 -2.0%
Opened positions 22 31 -29.0%
Closed positions 25 21 +19.0%
Increased positions 42 47 -10.6%
Reduced positions 47 39 +20.5%
13F shares Current Prev Q Change
Total value 281.94M 428.6M -34.2%
Total shares 44.92M 42.72M +5.1%
Total puts 521.2K 834.2K -37.5%
Total calls 1.14M 1.72M -33.6%
Total put/call ratio 0.5 0.5 -5.9%
Largest owners Shares Value Change
STT State Street 13.86M $69.86M +23.9%
BLK Blackrock 8.44M $42.55M -0.1%
Vanguard 6.07M $30.62M +1.5%
Geode Capital Management 2.23M $11.26M +6.7%
D. E. Shaw & Co. 1.59M $8.03M -25.1%
MS Morgan Stanley 1.25M $6.31M +546.4%
NTRS Northern Trust 1.2M $6.03M -2.9%
Rafferty Asset Management 996.46K $5.02M +17.5%
Charles Schwab Investment Management 905.31K $4.56M +2.1%
UBS UBS Group AG - Registered Shares 836.82K $4.22M +34.6%
Largest transactions Shares Bought/sold Change
STT State Street 13.86M +2.67M +23.9%
MS Morgan Stanley 1.25M +1.06M +546.4%
D. E. Shaw & Co. 1.59M -534.28K -25.1%
C Citigroup 162.13K -498.85K -75.5%
Susquehanna International 688.69K -322.53K -31.9%
NA National Bank of Canada 201 -316K -99.9%
UBS UBS Group AG - Registered Shares 836.82K +214.9K +34.6%
GS Goldman Sachs 434.68K +214.2K +97.1%
National Asset Management 0 -159.48K EXIT
Parametric Portfolio Associates 13.1K -148.81K -91.9%
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
PDS Biotechnology

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: aforementioned, American, animal, appeal, back, BioDelivery, career, Central, Chair, Chairperson, client, CMO, conclusion, construct, contest, Deloitte, disagreement, doubling, ESPP, Exhibit, expertise, family, fill, Florida, Fortune, hamster, hearing, hereto, hinder, inability, Institute, interval, Isicrate, journal, Karen, lapsed, Leader, listing, Marketplace, Marquette, Medicine, medRxiv, member, middle, mixture, Nasdaq, Omicron, parental, path, Paul, pharmaceutical, predecessor, proposed, qualified, reached, recommendation, Regulation, reject, resign, resignation, Restated, revert, Robert, science, Secretary, shifted, shorter, slightly, sooner, spent, Stipulation, successor, thereof, Tohmatsu, Touche, Translational, trending, undergraduate, unpaid, vacancy, variant, vigorously, Watson, Wilson, Yedid, younger
Removed: anticipated, capture, Chief, European, factor, gained, growth, Importantly, operate, President, Shionogi, topline, unvaccinated
From filing 10-Q 2022 Q2
Financial reports
View all
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
10-K
2021 FY
Annual report
24 Feb 22
10-Q
2021 Q3
Quarterly report
4 Nov 21
10-Q
2021 Q2
Quarterly report
5 Aug 21
10-Q
2021 Q1
Quarterly report
6 May 21
10-K
2020 FY
Annual report
25 Feb 21
10-Q
2020 Q3
Quarterly report
11 Nov 20
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
12 May 20
Current reports
View all
8-K
Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results
8 Aug 22
8-K/A
Vaxart Stockholders Approve Proxy Proposals 2, 3 and 4
5 Aug 22
8-K
Other Events
28 Jul 22
8-K
Submission of Matters to a Vote of Security Holders
8 Jul 22
8-K
Entry into a Material Definitive Agreement
6 Jul 22
8-K
Other Events
28 Jun 22
8-K
Management to discuss progress on its programs, annual stockholders’ meeting proposals
16 Jun 22
8-K
Vaxart Announces Adjournment of Annual Meeting of Stockholders
8 Jun 22
8-K
Other Events
6 Jun 22
8-K
Departure of Directors or Certain Officers
11 May 22
Registration and prospectus
View all
424B5
Prospectus supplement for primary offering
15 Sep 21
424B5
Prospectus supplement for primary offering
15 Sep 21
S-8
Registration of securities for employees
21 Jun 21
424B5
Prospectus supplement for primary offering
13 Oct 20
S-3ASR
Automatic shelf registration
8 Jul 20
S-8
Registration of securities for employees
7 Jul 20
424B5
Prospectus supplement for primary offering
2 Mar 20
424B4
Prospectus supplement with pricing info
27 Sep 19
POS AM
Prospectus update (post-effective amendment)
27 Sep 19
FWP
Free writing prospectus
25 Sep 19
Proxies
View all
DEFA14A
Additional proxy soliciting materials
26 Jul 22
DEFA14A
Additional proxy soliciting materials
26 Jul 22
DEFA14A
Additional proxy soliciting materials
12 Jul 22
DEFA14A
Additional proxy soliciting materials
1 Jul 22
DEFA14A
Additional proxy soliciting materials
1 Jul 22
DEFA14A
Additional proxy soliciting materials
24 Jun 22
DEFA14A
Additional proxy soliciting materials
25 May 22
DEFA14A
Additional proxy soliciting materials
18 May 22
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
Other
View all
UPLOAD
Letter from SEC
28 Jan 21
CORRESP
Correspondence with SEC
26 Jan 21
UPLOAD
Letter from SEC
21 Jan 21
CORRESP
Correspondence with SEC
7 Jan 21
UPLOAD
Letter from SEC
27 Dec 20
EFFECT
Notice of effectiveness
3 Oct 19
EFFECT
Notice of effectiveness
27 Sep 19
CORRESP
Correspondence with SEC
25 Sep 19
CORRESP
Correspondence with SEC
25 Sep 19
CORRESP
Correspondence with SEC
22 Sep 19
Ownership
View all
4
Vaxart / W. Mark Watson ownership change
8 Aug 22
4
Vaxart / Robert A. Yedid ownership change
8 Aug 22
4
Vaxart / David E. Wheadon ownership change
8 Aug 22
4
Vaxart / Michael J. Finney ownership change
8 Aug 22
4
Vaxart / Todd C Davis ownership change
8 Aug 22
4
Vaxart / Julie M Cherrington ownership change
8 Aug 22
3
Vaxart / W. Mark Watson ownership change
8 Aug 22
4
Vaxart / Fuad Ahmad ownership change
23 Jun 22
3
Vaxart / Fuad Ahmad ownership change
12 May 22
4
Vaxart / Sean Tucker ownership change
25 Apr 22

Transcripts

2022 Q2
Earnings call transcript
9 Aug 22

Reddit threads

View all